Gene · 1633
Papers2,658
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
201 to 220 of 2,658
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Deoxycytidine kinase (dCK) inhibition is synthetic lethal with BRCA2 deficiency. | Drug Resist Updat | 2023 | 36706533 | PubTator, text mining | PubMed |
| SAMHD1 single nucleotide polymorphisms impact outcome in children with newly diagnosed acute myeloid leukemia. | Blood Adv | 2023 | 36689724 | PubTator, text mining | PubMed |
| Profiling Sulfur(VI) Fluorides as Reactive Functionalities for Chemical Biology Tools and Expansion of the Ligandable Proteome. | ACS Chem Biol | 2023 | 36649130 | PubTator, text mining | PubMed |
Investigation of the Effects of Glabridin on the Proliferation, Apoptosis, and Migration of the Human Colon Cancer Cell Lines SW480 and SW620 and Its Mechanism Based on Reverse Virtual Screening and Proteomics. | Oxid Med Cell Longev | 2023 | 36644579 | PubTator, text mining | PubMed |
| Positron emission tomography molecular imaging to monitor anti-tumor systemic response for immune checkpoint inhibitor therapy. | Eur J Nucl Med Mol Imaging | 2023 | 36622406 | PubTator, text mining | PubMed |
| Repurposing MS immunotherapies for CIDP and other autoimmune neuropathies: unfulfilled promise or efficient strategy? | Ther Adv Neurol Disord | 2023 | 36620728 | PubTator, text mining | PubMed |
| DGKB mediates radioresistance by regulating DGAT1-dependent lipotoxicity in glioblastoma. | Cell Rep Med | 2023 | 36603576 | PubTator, text mining | PubMed |
| Barriers and opportunities for gemcitabine in pancreatic cancer therapy. | Am J Physiol Cell Physiol | 2023 | 36571444 | PubTator, text mining | PubMed |
Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high-dose chemotherapy independent of MIPI and complement established highrisk factors. | Haematologica | 2023 | 36519324 | PubTator, text mining | PubMed |
| Association of COVID-19 with endocarditis in patients with cocaine or opioid use disorders in the US. | Mol Psychiatry | 2023 | 36510003 | PubTator, text mining | PubMed |
Hypomethylating agent-based therapies in older adults with acute myeloid leukemia - A joint review by the Young International Society of Geriatric Oncology and European Society for Blood and Marrow Transplantation Trainee Committee. | J Geriatr Oncol | 2023 | 36435726 | PubTator, text mining | PubMed |
| A naïve pooled data approach for extrapolation of Phase 0 microdose trials to therapeutic dosing regimens. | Clin Transl Sci | 2023 | 36419385 | PubTator, text mining | PubMed |
| Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy. | Leukemia | 2023 | 36380143 | PubTator, text mining | PubMed |
| A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer. | Clin Cancer Res | 2023 | 36378548 | PubTator, text mining | PubMed |
| ENT1 blockade by CNX-774 overcomes resistance to DHODH inhibition in pancreatic cancer. | Cancer Lett | 2023 | 36341997 | PubTator, text mining | PubMed |
| Pharmacogenetics of ABCB1, CDA, DCK, GSTT1, GSTM1 and outcomes in a cohort of pediatric acute myeloid leukemia patients from Colombia. | Cancer Rep (Hoboken) | 2023 | 36316809 | PubTator, text mining | PubMed |
| Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells. | Mol Cell Biochem | 2023 | 36302993 | PubTator, text mining | PubMed |
| Genome-edited allogeneic donor "universal" chimeric antigen receptor T cells. | Blood | 2023 | 36223560 | PubTator, text mining | PubMed |
| TRIM67 drives tumorigenesis in oligodendrogliomas through Rho GTPase-dependent membrane blebbing. | Neuro Oncol | 2023 | 36215168 | PubTator, text mining | PubMed |
| Targeting deoxycytidine kinase improves symptoms in mouse models of multiple sclerosis. | Immunology | 2023 | 35986643 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1633/papers?page=11